Magazine Article | March 1, 2022

CMC And Quality Considerations When Engaging Your CDMO

Source: Life Science Leader

By Bikash Chatterjee, CEO, Pharmatech Associates

Deciding to use a CDMO to support your drug development program adds complexity and risk if the right partner is not identified and engaged. Before pursuing an outsourcing strategy, it is essential to define what processes will be kept in-house and where your CDMO partner will take the lead. This partner can be used to either spearhead or support several areas in the drug development road map, from the earliest stages in drug development through process characterization, tech transfer, and analytical method development to post-approval clinical commitments.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader